Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC

Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02999646
• Other study ID #: SAKK 11/16
• Status: Completed
• Phase: N/A
• Start date: July 25, 2018
• Est. completion date: June 29, 2023

Study information

• Verified date: January 2023
• Source: Maxivax SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 consists of dead tumor cells from the patient itself and genetically modified cells within a capsule. The whole treatment takes 9 weeks. At weeks 1, 2, 3, 4, 6 and 8, the tumor cells are injected underneath the skin and two capsules are implanted for a week. At weeks 2, 3, 4, 5, 7 and 9 the capsules are removed again. The patients are then followed-up for 5 years.

Description:

Patients with advanced HNSCC after platinum-based palliative chemotherapy have a poor prognosis, with no well-defined standard treatment and a survival between 6 to 9 months. MVX-ONCO-1 is a patient specific, cell-based, active immunotherapy, where the patient's immune response to tumor cells is stimulated and/or increased by triggering an immune response against the patients' cancer cells. Rationale for this trial is: 1. HNSCC: there is a clear medical need in this patient population, 2. Relapsing HNSCC often have accessible tumor tissue, 3. HNSCC is considered an immunogenic tumor. This phase II study is a first step towards a potentially innovative immunotherapy for HNSCC. MVX-ONCO-1 is composed of: 1. An immune-modulator (GM-CSF: granulocyte-macrophage colony stimulating factor) released from an immuno-protected, encapsulated, allogeneic, genetically modified cell line (MVX-1), and 2. Irradiated, autologous tumor cells as source of antigen. Each treatment consists of two macrocapsules containing the MVX-1 cell line implanted subcutaneously and lethally irradiated autologous tumor cells injected subcutaneously. Eligible patients will receive a treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each pair of macrocapsules is removed after 1 week, and the last implanted capsules are removed in week 9. The patients are then followed-up for 5 years. The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 880194.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: June 29, 2023
• Est. primary completion date: January 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for pre-registration:

• Written informed consent according to ICH/GCP regulations before pre-registration
• Histologically confirmed diagnosis of head and neck squamous carcinoma (oral cavity, pharynx, larynx), Stage III/IV in recurrent or metastatic stage. Patients with local relapse for whom a curative treatment is available cannot be enrolled. Furthermore, all patients should have no other therapeutic option left.
• At least one line of prior anticancer therapy for recurrent or metastatic disease. Patients with locally advanced disease experiencing local relapse within 6 months of last dose of curative intended, platinum-based chemo-radiation with or without prior surgery can also be included.
• Primary tumor and/or metastasis amenable for partial/total surgery or tap
• Measurable or evaluable disease according to RECIST 1.1 criteria
• Patients age = 18 years
• WHO performance status 0-2
• Adequate hematological values: neutrophils =1x10^9/L, platelets =70x10^9/L
• Adequate hepatic function: bilirubin =2 x ULN; AST and ALT and AP =2.5 x ULN (except for patients with liver metastasis: =5 x ULN)
• Adequate renal function (creatinine clearance >40mL/min/1.73m^2, calculated according to the corrected formula of Cockcroft-Gault
• Women with child-bearing potential are using effective contraception, are not pregnant and agree not to become pregnant after pre-registration, during trial treatment and during the 6 months thereafter. A negative blood pregnancy test before inclusion into the trial is required for all women with child-bearing potential
• Men agree not to father a child during trial treatment and during 6 months thereafter

Exclusion Criteria for pre-registration:

• Known or suspected CNS metastases or active leptomeningeal disease
• History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration with the exception of T1-2 prostate cancer Gleason score <6 (PSA<10 ng/mL), adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
• Participated in any other investigational study or received an experimental therapeutic procedure considered to interfere with the study in the 4 preceding weeks of the pre-registration
• Concomitant use of other anti-cancer drugs
• Planned radiotherapy (other than symptom control)
• Severe or uncontrolled cardiovascular disease uncontrolled hypertension (sustained systolic blood pressure > 150 mm Hg and/or diastolic > 100 mm Hg despite antihypertensive therapy)
• History of cerebrovascular accident or intracranial hemorrhage within 6 months prior to pre-registration
• Any history of HIV
• Known history of HTLV-1, HTLV-2, or active chronic Hepatitis C or Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment
• Known severe allergy to reagents in the study product (MVX-ONCO-1)
• Systemic disease other than cancer that is not controlled by approved medication
• Patient with active autoimmune disease
• Chronic immunosuppressive treatment exceeding 20 mg/day of prednisone or an equivalent corticosteroid. Note: In acute situations prednison exceeding 20mg/day or equivalent(day is allowed during 7 days)
• Women who are pregnant or breast feeding
• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications

Inclusion criteria for registration:

• Primary tumor and/or metastasis amenable for partial/total surgery or tap and subsequent cell harvest > 26x10^6 cells
• Measurable or evaluable disease according to RECIST 1.1 criteria
• WHO performance status 0-2
• Baseline QoL forms have been completed
• Adequate hematological values: neutrophils =1x10^9/L, platelets =70x10^9/L
• Adequate hepatic function: bilirubin =2 x ULN; AST and ALT and AP = 2.5 x ULN (except for patients with liver metastasis: =5 x ULN)
• Adequate renal function (creatinine clearance >40 mL/min/1.73m^2, calculated according to the corrected formula of Cockcroft-Gault
• Women with child-bearing potential are using effective contraception, are not pregnant or lactating and agree not to become pregnant after registration, during trial treatment, and during the 6 months thereafter. A negative blood pregnancy

Exclusion criteria for registration:

• Known or suspected CNS metastases or active leptomeningeal disease
• Concomitant use of other anti-cancer drugs
• Planned radiotherapy (other than symptom control)
• Any one full cycle of anti-cancer chemotherapy treatment in the 3 preceding weeks of the registration
• Systemic disease other than cancer, that is not controlled by approved medication
• Chronic immunosuppressive treatment exceeding 20 mg/day of prednisone or an equivalent corticosteroid. Note: In acute situations prednisone exceeding 20 mg/day or equivalent is allowed during 7 days
• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications
• Women who are pregnant or breastfeeding

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Other:
• MVX-ONCO-1
Autologous cells: 1 vial containing 4x10^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10^5 MVX-1 cells

Locations

Country	Name	City	State
Switzerland	HUG Hôpitaux Universitaires Genève	Geneva
Switzerland	Centre Hospitalier Universitaire Vaudois CHUV	Lausanne
Switzerland	Kantonsspital St. Gallen	St. Gallen
Switzerland	Universitätsspital Zürich	Zürich

Sponsors (2)

Lead Sponsor	Collaborator
Maxivax SA	European Commission

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival at 26 weeks (OS)	The primary endpoint of the trial is Overall Survival (OS) at 26 weeks defined as percentage of patients alive 26 weeks from registration. Patients who are lost to follow-up with a date they were last known to be alive less than 26 weeks after registration will be counted as failures for this endpoint.	at 26 weeks from registration
Secondary	Time to subsequent therapy (TST)	defined as time from registration until documented start of subsequent therapy. Patients who did not start a subsequent therapy will be censored at the last date they were known to be alive	assessed within 5 years
Secondary	Duration of response (DOR)	defined as time from the date when a patient first meets the criteria for complete response (CR) or partial response (PR) until documented radiologic progression, relapse, or death due to disease progression, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment. DOR will only be analyzed in the subgroup of patients achieving CR or PR during trial treatment based on RECIST 1.1.	assessed within 5 years
Secondary	Objective response rate (ORR)	defined as the proportion of patients having CR or PR at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.; The response rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later	at 6, 13, 26, 39 and 52 weeks
Secondary	Disease control rate (DCR)	defined as the proportion of patients having CR, PR, or stable disease (SD) at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration. The disease control rate will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.	at 6, 13, 26, 39 and 52 weeks
Secondary	Best overall response	defined as best response achieved at any time during or after the trial treatment before starting a new anticancer treatment. Best overall response will be analyzed based on RECIST 1.1. CR and PR will only be counted if the response is confirmed at least 4 weeks later.	assessed within 5 years
Secondary	Objective response according to iRECIST (iOR)	defined as any complete response (CR/iCR) or partial response (PR/iPR) according to RECIST1.1 or iRECIST criteria achieved before new anti-cancer treatment is given. Any patient with CR/iCR or PR/iPR as best observed response under trial treatment will be considered as a success; otherwise they will be considered as a failure. Patients without any tumor assessment or with non-evaluable response (NE) under trial treatment will be considered as failures for this endpoint.	at 6, 13, 26, 39 and 52 weeks
Secondary	Progression Free Survival (PFS)	defined as the time from registration until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting a new treatment.	assessed within 5 years
Secondary	Progression-free survival according to iRECIST (iPFS)	defined as the time from registration until disease progression according to iRECIST criteria (iPD) or death due to any reason, whichever occurs first.	assessed within 5 years
Secondary	PFS at 6, 13, 26, 39, and 52 weeks	will be estimated using the Kaplan-Meier estimator for PFS at the respective time point after registration plus/minus 1 week at week 6, 13, 26, and plus/minus 2 weeks at week 39 and 52 after registration.	at 6, 13, 26, 39, and 52 weeks
Secondary	OS	defined as time from registration until death from any cause. Patients which are still alive will be censored at the date they were last known to be alive.	assessed within 5 years
Secondary	PFS under the first subsequent treatment	defined as the time from start of the first subsequence treatment until progression according to RECIST 1.1 or death from any cause, whichever occurs first. Patients not having an event at the time of analysis and patients starting next line of anticancer therapy in the absence of an event will be censored at the date of their last tumor assessment showing non-progression before starting new treatment.	assessed within 5 years
Secondary	Adverse and serious adverse events	All adverse events (AE) will be assessed according to NCI CTCAE v4.0	assessed within 5 years